Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV - Get Free Report) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided earnings per share guidance of 5.450-5.650 for the period, compared to the consensus earnings per share estimate of 5.540. The company issued revenue guidance of -.

Solventum Price Performance

Shares of Solventum stock opened at $74.83 on Friday. The firm has a market cap of $12.95 billion and a PE ratio of 34.64. Solventum has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company's fifty day simple moving average is $69.36 and its two-hundred day simple moving average is $71.52.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.08 earnings per share. As a group, equities analysts expect that Solventum will post 6.58 EPS for the current year.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of recent analyst reports. Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $78.00 to $87.00 in a research report on Monday, May 19th. Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. The Goldman Sachs Group lifted their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Wells Fargo & Company lifted their target price on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. Finally, Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $80.29.

Institutional Trading of Solventum

A number of hedge funds have recently modified their holdings of SOLV. United Services Automobile Association bought a new stake in Solventum during the first quarter worth about $239,000. Woodline Partners LP boosted its position in shares of Solventum by 40.7% in the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company's stock worth $888,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock worth $1,268,000 after purchasing an additional 10,425 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.